First City Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$862K Sell
35,814
-75
-0.2% -$1.96K 0.42% 61
2026
Q1
$1.01M Sell
35,889
-50
-0.1% -$1.33K 0.53% 48
2025
Q4
$895K Sell
35,939
-3,723
-9% -$93.9K 0.47% 56
2025
Q3
$1.01M Sell
39,662
-4,038
-9% -$99.7K 0.55% 44
2025
Q2
$1.06M Sell
43,700
-4,300
-9% -$100K 0.61% 43
2025
Q1
$1.22M Sell
48,000
-3,368
-7% -$88.1K 0.73% 34
2024
Q4
$1.36M Sell
51,368
-646
-1% -$17.5K 0.73% 30
2024
Q3
$1.51M Buy
52,014
+6,431
+14% +$188K 0.77% 27
2024
Q2
$1.28M Sell
45,583
-4,699
-9% -$129K 0.72% 34
2024
Q1
$1.4M Sell
50,282
-4,105
-8% -$114K 0.77% 34
2023
Q4
$1.57M Sell
54,387
-5,096
-9% -$154K 0.91% 31
2023
Q3
$1.97M Buy
59,483
+37
+0.1% +$1.31K 1.24% 17
2023
Q2
$2.18M Sell
59,446
-521
-0.9% -$20.3K 1.29% 15
2023
Q1
$2.33M Sell
59,967
-6,851
-10% -$296K 1.36% 14
2022
Q4
$3.42M Sell
66,818
-645
-1% -$30.9K 2.06% 9
2022
Q3
$2.95M Sell
67,463
-859
-1% -$41.7K 1.95% 9
2022
Q2
$3.58M Buy
68,322
+1,588
+2% +$80.9K 2.21% 8
2022
Q1
$3.46M Sell
66,734
-712
-1% -$36.9K 1.9% 10
2021
Q4
$3.58M Buy
67,446
+1,290
+2% +$63.9K 2.01% 8
2021
Q3
$2.85M Buy
66,156
+2,250
+4% +$99.7K 1.6% 11
2021
Q2
$3.02M Sell
63,906
-378
-0.6% -$14.7K 1.66% 9
2021
Q1
$2.55M Buy
64,284
+2,070
+3% +$73.5K 1.48% 16
2020
Q4
$2.14M Sell
62,214
-56,776
-48% -$2.08M 1.37% 18
2020
Q3
$4.16M Buy
118,990
+55,717
+88% +$1.95M 1.55% 9
2020
Q2
$1.96M Buy
63,273
+1,024
+2% +$34.8K 1.51% 15
2020
Q1
$1.93M Sell
62,249
-1,085
-2% -$37K 1.89% 11
2019
Q4
$2.35M Sell
63,334
-29
-0% -$1.03K 1.62% 10
2019
Q3
$2.16M Sell
63,363
-2,425
-4% -$88.2K 1.58% 12
2019
Q2
$2.7M Sell
65,788
-79
-0.1% -$3.14K 1.97% 6
2019
Q1
$2.65M Sell
65,867
-2,916
-4% -$117K 1.91% 6
2018
Q4
$2.85M Sell
68,783
-23,789
-26% -$988K 2.22% 5
2018
Q3
$3.87M Sell
92,572
-730
-0.8% -$28.1K 2.57% 5
2018
Q2
$3.21M Buy
+93,302
New +$3.19M 2.3% 5
2018
Q1
Sell
-93,775
Closed -$3.22M 143
2017
Q4
$3.22M Sell
93,775
-2,005
-2% -$68.4K 2.2% 5
2017
Q3
$3.24M Sell
95,780
-1,104
-1% -$35.5K 2.27% 6
2017
Q2
$3.09M Buy
96,884
+6
+0% +$189 2.24% 6
2017
Q1
$3.14M Sell
96,878
-628
-0.6% -$19.8K 2.32% 6
2016
Q4
$3M Sell
97,506
-1,776
-2% -$54.2K 2.26% 8
2016
Q3
$3.19M Sell
99,282
-840
-0.8% -$28.1K 2.44% 7
2016
Q2
$3.35M Buy
100,122
+4
+0% +$128 2.53% 8
2016
Q1
$2.82M Sell
100,118
-2,337
-2% -$66.8K 1.93% 9
2015
Q4
$3.14M Buy
102,455
+913
+0.9% +$28.7K 2.11% 7
2015
Q3
$3.03M Sell
101,542
-399
-0.4% -$12.8K 2.22% 5
2015
Q2
$3.24M Buy
101,941
+1,529
+2% +$49.8K 2.25% 6
2015
Q1
$3.31M Sell
100,412
-1,921
-2% -$61.1K 2.29% 5
2014
Q4
$3.02M Sell
102,333
-586
-0.6% -$16.8K 2.09% 6
2014
Q3
$2.89M Sell
102,919
-843
-0.8% -$23.7K 2.07% 5
2014
Q2
$2.92M Sell
103,762
-1,897
-2% -$54.1K 2.08% 5
2014
Q1
$3.22M Sell
105,659
-1,529
-1% -$45.6K 2.3% 3
2013
Q4
$3.11M Sell
107,188
-6,315
-6% -$184K 2.55% 4
2013
Q3
$3.09M Buy
113,503
+1,107
+1% +$30.1K 2.56% 3
2013
Q2
$2.99M Buy
+112,396
New +$3.11M 2.73% 3

Other funds holding PFE

First City Capital Management's PFE Position: Q2 2026 in Review

First City Capital Management reduced its Pfizer (PFE) stake by 0.21% in Q2 2026, selling an estimated $1.96K and leaving 35,814 shares worth $862K. The position accounts for 0.42% of the portfolio, ranked #61.

First City Capital Management first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.16M in Q3 2020. 1,247 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • First City Capital Management held 35,814 shares of Pfizer worth $862K as of Q2 2026.
  • First City Capital Management sold 75 Pfizer shares in Q2 2026, an estimated $1.96K.
  • Pfizer made up 0.42% of First City Capital Management's portfolio in Q2 2026, its #61 holding.
  • First City Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • First City Capital Management's Pfizer position peaked at $4.16M in Q3 2020.
  • 1,247 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on First City Capital Management's 13F filing for Q2 2026, filed 13 Jul 2026.